A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies - Giles, F; Fischer, T; Cortes, J (Clin Cancer Res, 2006)
et al.